Innate Pharma Future Growth

Future criteria checks 3/6

Innate Pharma is forecast to grow earnings and revenue by 4.2% and 21.9% per annum respectively. EPS is expected to grow by 63.8% per annum. Return on equity is forecast to be 64.9% in 3 years.

Key information

4.2%

Earnings growth rate

63.85%

EPS growth rate

Biotechs earnings growth	25.5%
Revenue growth rate	21.9%
Future return on equity	64.90%
Analyst coverage	Low
Last updated	28 Jul 2025

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqGS:IPHA - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	60	-52	-70	-70	3
12/31/2026	95	-14	48	56	4
12/31/2025	72	-8	41	45	4
12/31/2024	20	-49	-7	-7	N/A
9/30/2024	27	-42	-14	-12	N/A
6/30/2024	34	-34	-20	-18	N/A
3/31/2024	48	-21	-28	-25	N/A
12/31/2023	62	-8	-35	-33	N/A
9/30/2023	57	-35	-34	-32	N/A
6/30/2023	52	-63	-33	-32	N/A
3/31/2023	55	-60	-27	-25	N/A
12/31/2022	58	-58	-20	-19	N/A
9/30/2022	57	-40	-24	-23	N/A
6/30/2022	57	-22	-28	-26	N/A
3/31/2022	41	-34	-44	-42	N/A
12/31/2021	25	-45	-60	-58	N/A
6/30/2021	46	-8	-27	-25	N/A
3/31/2021	58	-4	-45	-38	N/A
12/31/2020	70	-1	-63	-52	N/A
9/30/2020	67	-54	-78	-67	N/A
6/30/2020	63	-44	-93	-83	N/A
3/31/2020	75	-33	-62	-24	N/A
12/31/2019	85	8	-30	35	N/A
9/30/2019	108	5	-17	48	N/A
6/30/2019	130	31	-4	61	N/A
3/31/2019	112	17	-19	14	N/A
12/31/2018	94	3	-34	-33	N/A
9/30/2018	70	-19	N/A	-46	N/A
6/30/2018	46	-40	N/A	-59	N/A
3/31/2018	45	-44	N/A	-53	N/A
12/31/2017	44	-48	N/A	-48	N/A
9/30/2017	55	-28	N/A	-43	N/A
6/30/2017	66	-8	N/A	-38	N/A
3/31/2017	66	3	N/A	-37	N/A
12/31/2016	66	13	N/A	-37	N/A
9/30/2016	53	5	N/A	-33	N/A
6/30/2016	41	-2	N/A	-29	N/A
3/31/2016	33	-4	N/A	86	N/A
12/31/2015	25	-7	N/A	202	N/A
9/30/2015	17	-13	N/A	200	N/A
6/30/2015	8	-19	N/A	199	N/A
3/31/2015	8	-19	N/A	91	N/A
12/31/2014	8	-20	N/A	-18	N/A
9/30/2014	11	-15	N/A	-15	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPHA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IPHA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IPHA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IPHA's revenue (21.9% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: IPHA's revenue (21.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IPHA's Return on Equity is forecast to be very high in 3 years time (64.9%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/08/27 18:40
End of Day Share Price	2025/08/27 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Innate Pharma S.A. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Justin Zelin	BTIG
Yigal Nochomovitz	Citigroup Inc
Michael Thomas Cooper	Edison Investment Research

Innate Pharma Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Recent updates

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

Innate Pharma Highlights Anket® Abstracts for the Eha 2025 Congress

Innate Pharma SA Highlights Preclinical Anti-Tumor Efficacy Data of its Antibody Drug Conjugate IPH4502 at AACR Annual Meeting

Innate Pharma S.A. has completed a Follow-on Equity Offering in the amount of €14.999999 million.

Innate Pharma: Moving Into The Padcev Space

Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion

Innate Pharma S.A. Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Innate Pharma: Looking Like A Company We'll Regret Ignoring

Innate Pharma S.A., Annual General Meeting, May 22, 2025

Innate Pharma S.A. to Report First Half, 2025 Results on Sep 17, 2025

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma: Worth A Deeper Look

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma GAAP EPS of €0.08, revenue of €45.59M

Innate stock rises as Sanofi progress on 2nd cancer drug compound, pay €3M

Innate Pharma: Leading The NK Cell Immunotherapy Space